Second Quarter 2025 Earnings

July 30, 2025

IDEX CORPORATION

Trusted Solutions, Improving Lives™

Cautionary Statement

Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures

This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company’s third quarter 2025 and full year 2025 outlook including expected organic sales, expected earnings per share, and expected adjusted earnings per share and the assumptions underlying these expectations, anticipated future acquisition behavior and the anticipated benefits and performance of the Company’s recent or future acquisitions, resource and capital deployment and focus and organic and inorganic growth, the Company’s ability to adapt to macroeconomic challenges, anticipated impacts of tariffs and global trade policies and changes in law, including the One, Big, Beautiful Bill Act, anticipated trends in end markets, including expectations regarding future order volumes and order patterns, anticipated growth initiatives and expansions, and the anticipated benefits of the Company’s productivity and cost containment efforts and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “guidance,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “likely to be,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this presentation.

The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries; the impact of severe weather events, natural disasters and public health threats; economic and political consequences resulting from terrorist attacks and wars; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; cybersecurity incidents; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in countries in which the Company operates; developments with respect to trade policy and existing, new or increased tariffs or other similar measures; changes to applicable laws and regulations, including tax laws; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters.

Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports filed with the United States Securities and Exchange Commission (“SEC”) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this presentation, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included in this presentation and our earnings release which is available on our website.

IDEX CORPORATION

IDEX 2Q25 Highlights

- Delivered better than expected results despite macro uncertainty
- IDEX teams accelerated integrated growth strategies
- Inconsistent day rate pattern and slower customer decision making impacting second half forecast
- Stable activity and solid execution across IDEX
- Platform optimization and delayering plans on track

IDEX CORPORATION

Growth Platforms – Origins & Proven Benefits

IDEX Health & Science ("IH&S")

- Platform built over 20 years of diligent organic and inorganic capital deployment
- Scaled into an integrated global platform adding differentiated capabilities to core portfolio
- Recent component solution win with key analytical and diagnostics solutions customer
- History of MSD+ organic growth and delivering DD returns

Protein Analysis Instrument

Optical Technologies ("OT")

- Constructed over 14 years through organic and inorganic strategic initiatives
- Recently added Micro-LAM, a manufacturer of high precision, custom optical components

- 8020 initially focused to optimize profitability; moved to platform collaboration to support growth
- History of MSD+ organic growth with strong margin expansion (~6x improvement), and DD returns

Track record of building platforms where scalable growth intersects with increased value for customers

IDEX CORPORATION

Note: IDEX Health and Science (IH&S) and Optical Technologies, a component of IDEX Materials Science Solutions (MSS) are part of our Scientific Fluidics and Optics business within our HST segment.

Replicating IDEX Platform Success with MSS & Mott

Previous platform experiences, learnings and successes inform current and future platform builds

IDEX Materials Science Solutions

Leading-edge portfolio of applied materials forming solutions

Implementing 8020, integrated solutions exploration, and accelerated product innovation

Scaled growth through solving complex customer problems in advantaged end markets

OPTICAL TECHNOLOGIES + MUON + stc Material Solutions

mott MISSION CRITICAL PRECISION

Leader in design and manufacturing of sintered porous materials and flow control solutions

- *highly complementary to HST businesses*

Implementing 8020, and exploring many cross-collaboration opportunities

Tuning portfolio towards repeatable, IDEX-like and more highly-differentiated solutions

Driving strategic upside, backed by proven success

Note: IDEX Health and Science (IH&S), IDEX Materials Science Solutions (MSS), and Mott Corporation comprise our Scientific Fluidics and Optics business within our HST segment.

Q2 2025 Financial Performance

($ in millions excl. EPS)



	Organic*	FX	M&A	Y/Y ∆
Sales Growth	1%	1%	5%	7%

Organic* orders increased 2% y/y

Q2 results above expectations but order pattern choppy

IDEX CORPORATION

*This presentation contains non-GAAP financial information whose reconciliations are included in this presentation.

Q2 2025: Health & Science Technologies

($ in millions)

Orders

+2% Organic*



Sales

+4% Organic*



Adj. EBITDA Margin

-170 bps

	Organic*	FX	M&A	Y/Y Δ
Sales Growth	4%	1%	15%	20%

Revenue growth supported by positive price and pharma, space/defense, and data center

Highlights

- Continued strength in Pharma, Space/Defense, and Data Center
- Analytical Instrumentation steady with trend towards low single digit growth
- Soft semiconductor, auto, and industrial
- Adj EBITDA margin y/y results driven by Mott acquisition and unfavorable mix

Key Markets Health

	2025
Energy Transition/Data Center	+
Space/Defense	+
Analytical Instrumentation	✓
Semiconductor	−
Pharma/Food	+

+ *Positive Catalysts* ✓ *Stable / moderate lift* − *Flat / No signs of bounce back / Cyclically down*

CORPORATION

*This presentation contains non-GAAP financial information whose reconciliations are included in this presentation.

Q2 2025: Fluid & Metering Technologies

($ in millions)

Orders **+7% Organic*** | **Sales** **-2% Organic*** | **Adj. EBITDA Margin** **+130 bps**

	Organic*	FX	M&A	Y/Y Δ
Sales Growth	-2%	1%	-2%	-3%

Challenging prior year revenue comparable and strong Adjusted EBITDA Margin performance

Highlights

- Order growth across downstream energy, agriculture, and municipal water
- Chemical, water, energy, ag businesses faced tough y/y comparisons; semi soft
- Industrial day rates at expectation through May but declined in June
- Adj EBITDA margin y/y results driven by positive price/cost and net productivity improvements, partially offset by volume deleverage

Key Markets Health

	2025
Water Solutions & Services	✓
Downstream Energy	+
Diversified Industrials	✓
Agriculture	−

+ *Positive Catalysts* ✓ *Stable / moderate lift* − *Flat / No signs of bounce back / Cyclically down*

IDEX CORPORATION

*This presentation contains non-GAAP financial information whose reconciliations are included in this presentation.

Q2 2025: Fire & Safety / Diversified Products

($ in millions)

Orders	Sales	Adj. EBITDA Margin
-7% Organic*	+2% Organic*	+40 bps



	Organic*	FX	M&A	Y/Y Δ
Sales Growth	2%	1%	—%	3%

Revenue growth driven by Fire OEM demand, adoption of Fire integrated solutions, and strong BAND-IT

Highlights

- Fire and Safety continues to benefit from strong OEM demand and strong adoption of our integrated solutions
- Order timing effects across both Fire and Safety and Dispensing businesses
- BAND-IT experiencing share gains in Energy
- Adj EBITDA y/y results driven by positive price/cost, which more than offset unfavorable productivity, mix and volume deleverage

Key Markets Health

	2025
Fire & Rescue	✓
Auto	–
Dispensing	✓

+ Positive Catalysts *✓ Stable / moderate lift* *– Flat / No signs of bounce back / Cyclically down*

IDEX CORPORATION

*This presentation contains non-GAAP financial information whose reconciliations are included in this presentation.

2025 Guidance Summary

	Full Year Current Guidance	Third Quarter Current Guidance
Organic Revenue % vs Prior Year*	~1%	2% - 3%
Adjusted EBITDA %*	26.5% – 27.0%	26.0% – 26.5%
Reported Earnings Per Share	$6.30 - $6.44	$1.54 - $1.61
Adjusted Earnings Per Share*	$7.85 - $7.95	$1.90 - $1.95
Other Modeling Items:		
FX Impact on Sales (a)	~1%	~1%
Acquisition/Divesture Impact on Sales	~3%	~4%
Depreciation	~$77 Million	~$19 Million
Amortization	~$129 Million	~$33 Million
Net Interest	~$64 Million	~$16 Million
Restructuring charges	~$21 - $25 Million	~$1 - $3 Million
Capital Expenditures	~$90 Million	
Tax Rate	23.5% - 24%	~25%
Free Cash Flow % of Adjusted Net Income*+	100%+	
Corporate Costs	$104 - $105 Million	~$27 - $28 Million

(a) – Based on 6/30/2025 FX Rate
Earnings per share estimates exclude all future acquisitions

IDEX CORPORATION

*This presentation contains non-GAAP financial information whose reconciliations are included in this presentation.
+Reconciliations of the Company's Free Cash Flow as a percentage of Adjusted Net Income guidance to the most directly comparable GAAP financial measures cannot be provided without unreasonable efforts and are not provided herein because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations.

Flexible, Returns-Focused Capital Deployment

Growth Investments	Maintain Strong Balance Sheet and Return Capital to Shareholders
• Focused on organic growth • Tuck-in M&A to scale and expand critical business capabilities • Continued investments in cross-platform capabilities	• Financial and strategic flexibility afforded by strong cash generation • Preserve investment grade financial position • Deliver reliable and consistent dividends • Supplement returns with opportunistic share repurchases

On track to generate 100%+ Free Cash Flow Conversion+ in 2025*

IDEX CORPORATION

*This presentation contains non-GAAP financial information whose reconciliations are included in this presentation.
+Reconciliations of the Company's Free Cash Flow as a percentage of Adjusted Net Income guidance to the most directly comparable GAAP financial measures cannot be provided without unreasonable efforts and are not provided herein because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations.

IDEX Value Drivers

ORGANIC GROWTH + **INORGANIC GROWTH** + **MARGIN EXPANSION**

ORGANIC GROWTH
- Leading market entitlement
- Pricing execution
- Growth bets prioritization

INORGANIC GROWTH
- Strong funnel of M&A opportunities
- Fast growing companies
- Disciplined capital deployment

MARGIN EXPANSION
- Leading the IDEX Op Model
- 8020
- Leverage

Appendix

CORPORATION

Strategic Acquisition of Micro-LAM

Micro-LAM is a leading designer and manufacturer of custom precision optical components, ultra-precision diamond tools, and laser-assisted machining devices

- ✓ Specialized capabilities that complement and advance IDEX's Materials Science Solutions ("MSS") platform
- ✓ Highly engineered products used in mission-critical applications that require the highest degree of precision
- ✓ Vertical integration of laser-assisted diamond turning enhances MSS solutions
- ✓ Strategically aligned with IDEX footprint in space and defense segments
- ✓ Implementation of the Strategic Advantage is expected to drive near- and long-term shareholder value creation
- ✓ Expected to generate 2025 full year revenue of approximately $25M with non-GAAP EPS accretion in year 1



IDEX CORPORATION

Non-GAAP Reconciliations

IDEX CORPORATION

Table 1: Reconciliations of the Change in Net Sales to Organic Sales

	HST	FMT	FSDP	IDEX
	Three Months Ended June 30, 2025			
Change in net sales	20%	(3%)	3%	7%
Less:				
Net impact from acquisitions/divestitures[1]	15%	(2%)	—%	5%
Impact from foreign currency[2]	1%	1%	1%	1%
Change in organic net sales	4%	(2%)	2%	1%
	Six Months Ended June 30, 2025			
Change in net sales	15%	(5%)	3%	4%
Less:				
Net impact from acquisitions/divestitures[1]	14%	(2%)	—%	4%
Impact from foreign currency[2]	—%	—%	—%	—%
Change in organic sales	1%	(3%)	3%	—%

[1] Represents the sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture.

[2] The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales, and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period.

Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (dollars in millions)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	**2024**	**2025**	**2024**
Gross profit	**$ 392.2**	$ 366.8	**$ 761.1**	$ 724.2
Fair value inventory step-up charges	**—**	—	**—**	2.5
Adjusted gross profit	**$ 392.2**	$ 366.8	**$ 761.1**	$ 726.7
Net sales	**$ 865.4**	$ 807.2	**$ 1,679.7**	$ 1,607.7
Gross margin	**45.3%**	45.4%	**45.3%**	45.0%
Adjusted gross margin	**45.3%**	45.4%	**45.3%**	45.2%

IDEX CORPORATION

Table 3: Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	2024	2025	2024
Reported net income attributable to IDEX	$ 131.6	$ 141.3	$ 227.1	$ 262.7
Fair value inventory step-up charges	—	—	—	2.5
Tax impact on fair value inventory step-up charges	—	—	—	(0.5)
Restructuring expenses and asset impairments[3]	0.4	1.3	17.9	2.4
Tax impact on restructuring expenses and asset impairments	(0.2)	(0.3)	(4.3)	(0.6)
Gain on sale of business	—	(4.6)	—	(4.6)
Tax impact on gain of sale of business	—	—	—	—
Acquisition-related intangible asset amortization	32.0	23.9	63.5	48.5
Tax impact on acquisition-related intangible asset amortization	(7.3)	(5.5)	(14.7)	(11.1)
Adjusted net income attributable to IDEX	$ 156.5	$ 156.1	$ 289.5	$ 299.3
Reported diluted EPS attributable to IDEX	$ 1.74	$ 1.86	$ 3.00	$ 3.46
Fair value inventory step-up charges	—	—	—	0.03
Tax impact on fair value inventory step-up charges	—	—	—	(0.01)
Restructuring expenses and asset impairments[3]	0.01	0.02	0.24	0.03
Tax impact on restructuring expenses and asset impairments	—	—	(0.06)	(0.01)
Gain on sale of business	—	(0.06)	—	(0.06)
Tax impact on gain of sale of business	—	—	—	—
Acquisition-related intangible asset amortization	0.42	0.31	0.83	0.64
Tax impact on acquisition-related intangible asset amortization	(0.10)	(0.07)	(0.19)	(0.14)
Adjusted diluted EPS attributable to IDEX	$ 2.07	$ 2.06	$ 3.82	$ 3.94
Diluted weighted average shares outstanding	75.5	75.9	75.7	75.9

[3] This adjustment represents the amount of Restructuring expenses and asset impairments attributable to IDEX. Restructuring expenses and asset impairments of $0.7 million and $18.2 million on the Condensed Consolidated Statements of Income during the three and six months ended June 30, 2025, respectively, included charges of $0.6 million recognized by the Company's joint venture, $0.3 million of which was attributable to noncontrolling interest.

Table 4: Reconciliations of Net Income to Adjusted EBITDA (dollars in millions)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	**2024**	**2025**	**2024**
Reported net income	**$ 131.1**	$ 141.2	**$ 226.5**	$ 262.5
Provision for income taxes	**38.8**	38.0	**67.9**	71.2
Interest expense - net	**15.6**	8.1	**31.7**	17.5
Gain on sale of business	**—**	(4.6)	**—**	(4.6)
Depreciation	**19.0**	16.3	**37.4**	32.5
Amortization	**32.0**	23.9	**63.5**	48.5
Fair value inventory step-up charges	**—**	—	**—**	2.5
Restructuring expenses and asset impairments	**0.7**	1.3	**18.2**	2.4
Adjusted EBITDA	**$ 237.2**	$ 224.2	**$ 445.2**	$ 432.5
Adjusted EBITDA Components:				
HST	**95.0**	84.2	**182.4**	165.6
FMT	**108.7**	107.7	**204.0**	213.1
FSDP	**56.4**	53.8	**110.6**	105.2
Corporate and other	**(22.9)**	(21.5)	**(51.8)**	(51.4)
Total Adjusted EBITDA	**$ 237.2**	$ 224.2	**445.2**	$ 432.5
Net sales	**865.4**	807.2	**1,679.7**	1,607.7
Net income margin	**15.1%**	17.5%	**13.5%**	16.3%
Adjusted EBITDA margin	**27.4%**	27.8%	**26.5%**	26.9%

CORPORATION

Table 5: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (dollars in millions)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	**2024**	**2025**	**2024**
Cash flows from operating activities	**$ 161.7**	$ 133.6	**$ 267.4**	$ 290.2
Less: Capital expenditures	**14.8**	15.9	**29.1**	35.9
Free cash flow	**$ 146.9**	$ 117.7	**$ 238.3**	$ 254.3
Reported net income attributable to IDEX	**$ 131.6**	$ 141.3	**$ 227.1**	$ 262.7
Adjusted net income attributable to IDEX	**156.5**	156.1	**289.5**	299.3
Operating cash flow conversion	**123%**	95%	**118%**	110%
Free cash flow conversion	**94%**	75%	**82%**	85%

IDEX CORPORATION

Table 6: Reconciliation of Estimated 2025 Change in Net Sales to Change in Organic Sales

	Guidance[3]			
	Third Quarter 2025		Full Year 2025	
	Low End	High End	Low End	High End
Estimated change in net sales	7%	9%	5%	6%
Less:				
Net impact from acquisitions/divestitures[1]	4%	4%	3%	3%
Impact from foreign currency[2]	1%	1%	1%	1%
Estimated change in organic sales	2%	3%	1%	1%

Table 7: Reconciliation of Estimated 2025 Diluted EPS Attributable to IDEX to Adjusted Diluted EPS Attributable to IDEX

	Guidance[3]	
	Third Quarter 2025	Full Year 2025
Estimated diluted EPS attributable to IDEX	$1.54 - $1.61	$6.30 - $6.44
Restructuring expenses and asset impairments[4]	$0.04 - $0.01	$0.33 - $0.28
Tax impact on restructuring expenses and asset impairments	$(0.01) - $0.00	$(0.07) - $(0.06)
Acquisition-related intangible asset amortization	$0.43	$1.69
Tax impact on acquisition-related intangible asset amortization	$(0.10)	$(0.40)
Estimated adjusted diluted EPS attributable to IDEX	$1.90 - $1.95	$7.85 - $7.95

(1) Represents the sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture.

(2) The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales, and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period.

(3) Amounts may not foot or recalculate precisely due to rounding.

(4) Represents estimated restructuring costs to be incurred during the remainder of 2025, primarily related to severance.

IDEX CORPORATION

Table 8: Reconciliation of Estimated 2025 Net Income to Adjusted EBITDA (dollars in millions)

	Guidance[2]			
	Third Quarter 2025		Full Year 2025	
	Low End	High End	Low End	High End
Estimated Reported net income	$ 116.2	$ 121.8	$ 476.2	$ 487.2
Provision for income taxes	38.3	40.2	148.0	151.5
Interest expense - net	16.4	16.4	63.7	63.7
Depreciation	19.5	19.5	76.6	76.6
Amortization of intangible assets	32.5	32.5	128.5	128.5
Restructuring expenses and asset impairments[1]	3.0	1.0	25.0	21.0
Estimated Adjusted EBITDA	$ 225.9	$ 231.4	$ 918.0	$ 928.5
Estimated Net sales	$ 853.8	$ 867.8	$ 3,425.0	$ 3,455.0
Estimated Net income margin	13.6%	14.0%	13.9%	14.1%
Estimated Adjusted EBITDA margin	26.0%	26.5%	26.5%	27.0%

[1] Represents estimated restructuring costs to be incurred during the remainder of 2025, primarily related to severance.

[2] Amounts may not foot or recalculate precisely due to rounding.

IDEX CORPORATION